Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Finished Goods (2024 - 2025)

Syndax Pharmaceuticals (SNDX) has 2 years of Finished Goods data on record, last reported at $2.2 million in Q3 2025.

  • For Q3 2025, Finished Goods changed N/A year-over-year to $2.2 million; the TTM value through Sep 2025 reached $2.2 million, changed N/A, while the annual FY2024 figure was $36000.0, N/A changed from the prior year.
  • Finished Goods reached $2.2 million in Q3 2025 per SNDX's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $2.3 million in Q1 2025 and bottomed at $36000.0 in Q4 2024.